The DOI matches its Crossref record; 295 of the 299 references it cites were found in a registry or an index.
Interpretation of the evidence for the efficacy and safety of statin therapy
Open accessAbstract
This Review is intended to help clinicians, patients, and the public make informed decisions about statin therapy for the prevention of heart attacks and strokes. It explains how the evidence that is available from randomised controlled trials yields reliable information about both the efficacy and safety of statin therapy. In addition, it discusses how claims that statins commonly cause adverse effects reflect a failure to recognise the limitations of other sources of evidence about the effects of treatment. Large-scale evidence from randomised trials shows that statin therapy reduces the risk of major vascular events (ie, coronary deaths or myocardial infarctions, strokes, and coronary revascularisation procedures) by about one-quarter for each mmol/L reduction in LDL cholesterol during each year (after the first) that it continues to be taken. The absolute benefits of statin therapy depend on an individual's absolute risk of occlusive vascular events and the absolute reduction in LDL cholesterol that is achieved. For example, lowering LDL cholesterol by 2 mmol/L (77 mg/dL) with an effective low-cost statin regimen (eg, atorvastatin 40 mg daily, costing about £2 per month) for 5 years in 10 000 patients would typically prevent major vascular events from occurring in about 1000 patients (ie, 10% absolute benefit) with pre-existing occlusive vascular disease (secondary prevention) and in 500 patients (ie, 5% absolute benefit) who are at increased risk but have not yet had a vascular event (primary prevention). Statin therapy has been shown to reduce vascular disease risk during each year it continues to be taken, so larger absolute benefits would accrue with more prolonged therapy, and these benefits persist long term. The only serious adverse events that have been shown to be caused by long-term statin therapy-ie, adverse effects of the statin-are myopathy (defined as muscle pain or weakness combined with large increases in blood concentrations of creatine kinase), new-onset diabetes mellitus, and, probably, haemorrhagic stroke. Typically, treatment of 10 000 patients for 5 years with an effective regimen (eg, atorvastatin 40 mg daily) would cause about 5 cases of myopathy (one of which might progress, if the statin therapy is not stopped, to the more severe condition of rhabdomyolysis), 50-100 new cases of diabetes, and 5-10 haemorrhagic strokes. However, any adverse impact of these side-effects on major vascular events has already been taken into account in the estimates of the absolute benefits. Statin therapy may cause symptomatic adverse events (eg, muscle pain or weakness) in up to about 50-100 patients (ie, 0·5-1·0% absolute harm) per 10 000 treated for 5 years. However, placebo-controlled randomised trials have shown definitively that almost all of the symptomatic adverse events that are attributed to statin therapy in routine practice are not actually caused by it (ie, they represent misattribution). The large-scale evidence available from randomised trials also indicates that it is unlikely that large absolute excesses in other serious adverse events still await discovery. Consequently, any further findings that emerge about the effects of statin therapy would not be expected to alter materially the balance of benefits and harms. It is, therefore, of concern that exaggerated claims about side-effect rates with statin therapy may be responsible for its under-use among individuals at increased risk of cardiovascular events. For, whereas the rare cases of myopathy and any muscle-related symptoms that are attributed to statin therapy generally resolve rapidly when treatment is stopped, the heart attacks or strokes that may occur if statin therapy is stopped unnecessarily can be devastating.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although LDL-lowering drugs have only moderate effects on TG levels, they reduce ASCVD risk in patients with and without HTG.42”
From Clinical review on triglycerides (2020) · cites this paper as [42]
Experimental — accuracy not yet measuredIn the citing paper
“Although LDL-lowering drugs have only moderate effects on TG levels, they reduce ASCVD risk in patients with and without HTG.42”
From Clinical review on triglycerides (2020) · cites this paper as [42]
In the citing paper
“Overall, statin therapy produced a 21% relative reduction in major vascular events (relative risk 0.79, 95% CI 0.77-0.81) per 1.0 mmoL/L reduction in LDL-C”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [217]
In the citing paper
“However, since the absolute risk of CAD is higher in older persons, the associated absolute increase in risk for a given increment in TC is larger with increasing age [217].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [217]
In the citing paper
“The relative reduction in major vascular events was similar, irrespective of age, among patients with pre-existing vascular disease, but appeared smaller among older individuals not known to have vascular disease.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [217]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Reduced dietary salt for the prevention of cardiovascular disease
Taylor, R. S., Ashton, K. E., Moxham, T., Hooper, L., & Ebrahim, S. B. J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009217.pub2 · Cited by 311
RetractedWriting Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
Self-citationRosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Research works printed but not linked: 3
- Abramson, 2013, Don't Give More Patients Statins, The New York Times
- 2013, Statins can weaken muscles and joints: cholesterol drug raises risk of problems by up to 20 per cent, MailOnline
- 2016, How Big Pharma greed is killing tens of thousands around the world: Patients are over-medicated and often given profitable drugs with ‘little proven benefits,’ leading doctors warn, MailOnline
Cited by
Sorted by citations
Items 201–300 of 1,000
Ofori‐Asenso, R., Jakhu, A., Curtis, A. J., Zomer, E., Gambhir, M., Korhonen, M. J., Nelson, M. R., Tonkin, A. M., Liew, D., & Zoungas, S. (2018) · The Journals of Gerontology Series A · doi:10.1093/gerona/glx256 · Cited by 71
Gut bacterial microbiome composition and statin intake—A systematic review
Dias, A. M., Cordeiro, G., Estevinho, M. M., Veiga, R., Figueira, L., Reina‐Couto, M., & Magro, F. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.601 · Cited by 71
Multimodality Intravascular Imaging of High-Risk Coronary Plaque
Li, J., Montarello, N. J., Hoogendoorn, A., Verjans, J. W. H., Bursill, C. A., Peter, K., Nicholls, S. J., McLaughlin, R. A., & Psaltis, P. J. (2021) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2021.03.028 · Cited by 68
How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol
Karagiannis, A. D., Mehta, A., Dhindsa, D. S., Virani, S. S., Orringer, C. E., Blumenthal, R. S., Stone, N. J., & Sperling, L. S. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1080 · Cited by 70
Self-citationThe Effect of Statins through Mast Cells in the Pathophysiology of Atherosclerosis: a Review
Kouhpeikar, H., Delbari, Z., Sathyapalan, T., Simental‐Mendía, L. E., Jamialahmadi, T., & Sahebkar, A. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00837-9 · Cited by 66
The Interdependency and Co-Regulation of the Vitamin D and Cholesterol Metabolism
Warren, T., McAllister, R., Morgan, A. E., Singh, T., McGilligan, V., Ennis, M., Page, C. J., Kelly, C., Peace, A. J., Corfe, B. M., et al. (2021) · Cells · doi:10.3390/cells10082007 · Cited by 68
Kinnear, F. J., Wainwright, E. M., Perry, R. E., Lithander, F. E., Bayly, G. R., Huntley, A. L., Cox, J. S., Hamilton-Shield, J. P., & Searle, A. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-030290 · Cited by 65
Coronary artery calcium scoring: an evidence‐based guide for primary care physicians
Cheong, B., Wilson, J. M., Spann, S., Pettigrew, R. I., Preventza, O. A., & Muthupillai, R. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13176 · Cited by 68
Molero, Y., Cipriani, A., Larsson, H., Lichtenstein, P., D'Onofrio, B. M., & Fazel, S. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30311-4 · Cited by 67
Zimmermann, F. M., Ding, V. Y., Pijls, N. H. J., Piróth, Z., van Straten, A. H. M., Szekely, L., Davidavičius, G., Kalinauskas, G., Mansour, S., Kharbanda, R. K., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.065770 · Cited by 68
Reiger, S., Jardim, T. V., Abrahams‐Gessel, S., Crowther, N. J., Wade, A. N., Gómez-Olivé, F. X., Salomon, J. A., Tollman, S. M., & Gaziano, T. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187347 · Cited by 64
Giugliano, R. P., Mach, F., Zavitz, K. H., Kurtz, C. E., Schneider, J., Wang, H., KEECH, A. C., Pedersen, T. R., Sabatine, M. S., Sever, P. S., et al. (2017) · Clinical Cardiology · doi:10.1002/clc.22678 · Cited by 64
Self-citationInflammatory Cytokines and Atherosclerotic Plaque Progression. Therapeutic Implications
Sterpetti, A. V. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00891-3 · Cited by 60
Hoffmann, U., Lu, M. T., Olalere, D., Adami, E. C., Osborne, M. T., Ivanov, A. S., Aluru, J. S., Lee, S., Arifovic, N., Overton, E. T., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.02.011 · Cited by 65
Ko, M. J., Jo, A. J., Kim, Y. J., Kang, S. H., Cho, S., Jo, S., Park, C., Yun, S., Lee, W. J., & Park, D. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011320 · Cited by 63
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes
Bhatt, D. L., Briggs, A. H., Reed, S. D., Annemans, L., Szarek, M. J., Bittner, V., Díaz, R., Goodman, S. G., Harrington, R. A., Higuchi, K., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.029 · Cited by 63
Richardson, T. G., Wang, Q., Sanderson, E. C. M., Mahajan, A., McCarthy, M. I., Frayling, T. M., Ala‐Korpela, M., Sniderman, A. D., Smith, G. D., & Holmes, M. V. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00086-6 · Cited by 61
Self-citationLong-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease
The HPS3/TIMI55-REVEAL Collaborative Group, Sammons, E. L., Hopewell, J. C., Chen, F., Stevens, W., Wallendszus, K., Valdés‐Márquez, E., Dayanandan, R., Knott, C., Murphy, K., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab863 · Cited by 62
Self-citationBeyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
Raschi, E., Casula, M., Cicero, A. F. G., Corsini, A., Borghi, C., & Catapano, A. L. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108507 · Cited by 67
Diabetes Secondary to Treatment with Statins
Laakso, M., & Kuusisto, J. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0837-8 · Cited by 61
Sarraju, A., Brennan, D. M., Hayden, K., Stronczek, A., Goldberg, A. C., Michos, E. D., McGuire, D. K., Mason, D., Tercek, G., Nicholls, S. J., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00721-4 · Cited by 64
Perioperative statin therapy in cardiac surgery: a meta-analysis of randomized controlled trials
Putzu, A., Capelli, B., Belletti, A., Cassina, T., Ferrari, E., Gallo, M., Casso, G., & Landoni, G. (2016) · Critical Care · doi:10.1186/s13054-016-1560-6 · Cited by 61
Wan, E. Y. F., Fung, C. S. C., Yu, E. Y. T., Chin, W. Y., Fong, D., Chan, A. K. C., & Lam, C. L. K. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006400 · Cited by 60
Nanoplumbers: biomaterials to fight cardiovascular diseases
Dormont, F., Varna, M., & Couvreur, P. (2017) · Materials Today · doi:10.1016/j.mattod.2017.07.008 · Cited by 61
Ridker, P. M., Rose, L. M., Kastelein, J. J. P., Santos, R. D., Wei, C., Revkin, J. H., Yunis, C., Tardif, J., & Shear, C. L. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.03.088 · Cited by 61
Self-citationHealth Benefits of Anti-aging Drugs
Piskovatska, V., Strilbytska, O. M., Koliada, A. K., Vaiserman, A. M., & Lushchak, O. V. (2019) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-981-13-3681-2_13 · Cited by 62
Mazhar, F., Hjemdahl, P., Clase, C. M., Johnell, K., Jernberg, T., Sjölander, A., & Carrero, J. J. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025813 · Cited by 60
Atherogenic Dyslipidemia in Latin America: Prevalence, causes and treatment
Ponte-Negretti, C. I., Isea-Perez, J. E., Lorenzatti, A. J., López-Jaramillo, P. A., Wyss-Q, F. S., Pintó, X., Lanas, F. T., Medina, J., Machado-H, L. T., Mónica Acevedo, B., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.05.059 · Cited by 66
Appropriateness of statin prescription in the elderly
Ruscica, M., Macchi, C., Pavanello, C., Corsini, A., Sahebkar, A., & Sirtori, C. R. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.12.011 · Cited by 61
Ruscica, M., Pavanello, C., Gandini, S., Macchi, C., Botta, M., Dall’Orto, D., Puppo, M. D., Bertolotti, M., Bosisio, R., Mombelli, G. G., et al. (2019) · Nutrition Journal · doi:10.1186/s12937-019-0438-2 · Cited by 60
Carr, D. F., Francis, B., Jorgensen, A., Zhang, E., Chinoy, H., Heckbert, S. R., Bis, J. C., Brody, J. A., Floyd, J. S., Psaty, B. M., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1557 · Cited by 61
Amarenco, P., Kim, J. S., Labreuche, J., Charles, H., Giroud, M., Lee, B., Mahagne, M., Nighoghossian, N., Steg, P. G., Vicaut, É., et al. (2020) · Stroke · doi:10.1161/strokeaha.119.028718 · Cited by 59
Zeitlinger, M. A., Bauer, M., Reindl‐Schwaighofer, R., Stoekenbroek, R. M., Lambert, G. C., Berger–Sieczkowski, E., Lagler, H., Oesterreicher, Z. A., Wulkersdorfer, B., Lührs, P., et al. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03149-2 · Cited by 59
Statins and cognition: Modifying factors and possible underlying mechanisms
Jamshidnejad-Tosaramandani, T., Kashanian, S., Al-Sabri, M. H., Kročianová, D., Clemensson, L. E., Gentreau, M., & Schiöth, H. B. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.968039 · Cited by 60
The Role of Toll-like Receptors in Atherothrombotic Cardiovascular Disease
Zhou, Y., Little, P. J., Downey, L., Afroz, R., Wu, Y., Ta, H. T., Xu, S., & Kamato, D. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00100 · Cited by 59
Kosowski, M., Smolarczyk, J., Hachuła, M., Maligłówka, M., Basiak, M., Machnik, G., Pudło, R., & Okopień, B. (2021) · Molecules · doi:10.3390/molecules26102838 · Cited by 60
Lewek, J., Niedziela, J. T., Desperak, P., Dyrbuś, K., Osadnik, T., Jankowski, P., Witkowski, A., Bielecka-Dabrowa, A. M., Dudek, D., Gierlotka, M. J., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030414 · Cited by 57
In vitro antibacterial effects of statins against bacterial pathogens causing skin infections
Ko, H. H. T., Lareu, R. R., Dix, B. R., & Hughes, J. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3227-5 · Cited by 57
Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management
Mytilinaiou, M. G., Kyrou, I., Khan, M., Grammatopoulos, D. K., & Randeva, H. S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00707 · Cited by 61
Jacobson, T. A., Cheeley, M. K., Jones, P. H., Forge, R. L., Maki, K. C., López, J. A. G., Xiang, P., Bushnell, D. M., Martin, M. L., & Cohen, J. D. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.04.011 · Cited by 57
Cai, Y., Wen, J., Ma, S., Mai, Z., Zhan, Q., Wang, Y., Zhang, Y., Chen, H., Li, H., Wu, W., et al. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.666449 · Cited by 56
Medicinal and edible plants in the treatment of dyslipidemia: advances and prospects
Hu, Y., Chen, X., Hu, M., Zhang, D., Yuan, S., Li, P., & Feng, L. (2022) · Chinese Medicine · doi:10.1186/s13020-022-00666-9 · Cited by 61
PPAR-α agonists are still on the rise: an update on clinical and experimental findings
Ferri, N., Corsini, A., Sirtori, C. R., & Ruscica, M. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1312339 · Cited by 59
Statin initiations and QRISK2 scoring in UK general practice: a THIN database study
Finnikin, S., Ryan, R. P., & Marshall, T. P. (2017) · British Journal of General Practice · doi:10.3399/bjgp17x693485 · Cited by 56
Present therapeutic role of cholesteryl ester transfer protein inhibitors
Ferri, N., Corsini, A., Sirtori, C. R., & Ruscica, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.028 · Cited by 56
Current state and future perspective of drug repurposing in malignant glioma
Siegelin, M. D., Schneider, E., Westhoff, M., Wirtz, C. R., & Karpel‐Massler, G. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.018 · Cited by 56
Shear stress and ROS-responsive biomimetic micelles for atherosclerosis via ROS consumption
Shen, M., Li, H., Yao, S., Wu, X., Liu, S., Yang, Q., Zhang, Y., Du, J., Qi, S., & Li, Y. (2021) · Materials Science and Engineering C · doi:10.1016/j.msec.2021.112164 · Cited by 55
Li, Y., Ji, X., Wu, H., Xiang, L., Zhang, H., & Tang, D. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114207 · Cited by 55
Mujwara, D., Henno, G., Vernon, S. T., Peng, S., Domenico, P. D., Schroeder, B. E., Busby, G., Figtree, G. A., & Bottà, G. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.025236 · Cited by 53
Vered, S., Paz, S., Negev, M., Tanné, D., Zucker, I., & Weinstein, G. (2020) · Environmental Research · doi:10.1016/j.envres.2020.109678 · Cited by 54
Ala‐Korpela, M. (2019) · International Journal of Epidemiology · doi:10.1093/ije/dyz068 · Cited by 54
Hartmann-Boyce, J., Theodoulou, A., Oke, J. L., Butler, A. R., Bastounis, A., Dunnigan, A., Byadya, R., Cobiac, L. J., Scarborough, P., Hobbs, F. D. R., et al. (2023) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.122.009348 · Cited by 53
Statins for primary prevention of cardiovascular disease
Byrne, P., Cullinan, J., & Smith, S. M. (2019) · BMJ · doi:10.1136/bmj.l5674 · Cited by 53
De Giorgi, R., De Crescenzo, F., Rizzo Pesci, N., Martens, M., Howard, W., Cowen, P. J., & Harmer, C. J. (2021) · PLOS ONE · doi:10.1371/journal.pone.0249409 · Cited by 52
Baumgartner, S., Bruckert, É., Gallo, A., & Plat, J. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.07.019 · Cited by 57
Adhikari, A., Tripathy, S., Chuzi, S., Peterson, J., & Stone, N. J. (2021) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2020.10.007 · Cited by 52
Cost-Effectiveness of Lipid-Lowering Treatments in Young Adults
Kohli-Lynch, C. N., Bellows, B. K., Zhang, Y., Spring, B. J., Kazi, D. S., Pletcher, M. J., Vittinghoff, E., Allen, N. B., & Moran, A. E. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.065 · Cited by 54
Packard, C. J. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-00994-z · Cited by 54
Advances in statin adverse reactions and the potential mechanisms: A systematic review
Zeng, W., Deng, H., Luo, Y., Zhong, S., Huang, M., & Tomlinson, B. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.12.020 · Cited by 58
Schiele, F., Ecarnot, F., & Chopard, R. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317706586 · Cited by 56
Awad, K., Mikhailidis, D. P., Toth, P. P., Jones, S. R., Moriarty, P. M., Lip, G. Y. H., Muntner, P., Catapano, A. L., Pencina, M. J., Rosenson, R. S., et al. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6743-0 · Cited by 52
Cholesterol-Lowering Agents: Statins—For Everyone?
Hadjiphilippou, S., & Ray, K. K. (2019) · Circulation Research · doi:10.1161/circresaha.118.313245 · Cited by 49
Hot topics and trends in cardiovascular research
Gal, D., Thijs, B., Glänzel, W., & Sipido, K. R. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz282 · Cited by 52
Saeed, A., & Ballantyne, C. M. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.007 · Cited by 51
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths
Scirica, B. M., Lincoff, A. M., Lingvay, I., Bogdanski, P., Buscemi, S., Colhoun, H., Craciun, A.-E., Ezhov, M., Hardt-Lindberg, S., Kleist Jeppesen, O., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.007 · Cited by 51
Banach, M., Catapano, A. L., Cicero, A. F. G., Escobar, C., Föger, B., Katsiki, N., Latkovskis, G., Rakowski, M., Reiner, Ž., Sahebkar, A., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106370 · Cited by 51
Statins in the treatment of depression: Hype or hope?
Köhler‐Forsberg, O., Otte, C., Gold, S. M., & Østergaard, S. D. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107625 · Cited by 52
Barbera, M., Mangialasche, F., Jongstra, S., Guillemont, J., Ngandu, T., Beishuizen, C. R. L., Coley, N., Brayne, C., Andrieu, S., Richard, E., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170858 · Cited by 50
Zwartjes, M., Gerdes, V. E. A., & Nieuwdorp, M. (2021) · Metabolites · doi:10.3390/metabo11080531 · Cited by 52
Marcus, M. E., Ebert, C. L., Geldsetzer, P., Theilmann, M., Bicaba, B. W., Andall‐Brereton, G., Bovet, P., Farzadfar, F., Gurung, M. S., Houéhanou, C., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003841 · Cited by 51
Mirzaei-Kalar, Z. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.08.033 · Cited by 50
Management of Blood Cholesterol
Alenghat, F. J., & Davis, A. M. (2019) · JAMA · doi:10.1001/jama.2019.0015 · Cited by 50
Magavern, E. F., Kaski, J. C., Turner, R. M., Drexel, H., Janmohamed, A., Scourfield, A., Burrage, D., Floyd, C. N., Adeyeye, E., Tamargo, J. L., et al. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab018 · Cited by 55
Oyama, K., Giugliano, R. P., Tang, M., Bonaca, M. P., Saver, J. L., Murphy, S. A., Ruzza, A., KEECH, A. C., Sever, P. S., Sabatine, M. S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab604 · Cited by 50
Self-citationPalmer, M. K., Barter, P. J., Lundman, P., Nicholls, S. J., Toth, P. P., & Karlson, B. W. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2018.10.011 · Cited by 49
Legacy effects of statins on cardiovascular and all-cause mortality: a meta-analysis
Nayak, A., Hayen, A. D., Zhu, L., McGeechan, K., Glasziou, P., Irwig, L., Doust, J. A., Gregory, G. A., & Bell, K. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020584 · Cited by 53
Roberts, R., Chang, C. C., & Hadley, T. D. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2020.09.004 · Cited by 54
Statins in Depression: An Evidence-Based Overview of Mechanisms and Clinical Studies
Giorgi, R. D., Pesci, N. R., Quinton, A. M. G., Crescenzo, F. D., Cowen, P. J., & Harmer, C. J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.702617 · Cited by 50
New onset diabetes mellitus induced by statins: current evidence
Chrysant, S. G. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1292107 · Cited by 49
Humphries, S. E., Cooper, J. A., Dale, P., & Ramaswami, U. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.11.005 · Cited by 50
The Immunomodulatory Effects of Statins on Macrophages
Sheridan, A., Wheeler-Jones, C. P. D., & Gage, M. C. (2022) · Immuno · doi:10.3390/immuno2020021 · Cited by 48
Statins and prostate cancer—hype or hope? The epidemiological perspective
Craig, E. L., Stopsack, K. H., Evergren, E., Penn, L. Z., Freedland, S. J., Hamilton, R. J., & Allott, E. H. (2022) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-022-00554-1 · Cited by 48
Statin prevents cancer development in chronic inflammation by blocking interleukin 33 expression
Park, J. H., Mortaja, M., Son, H. G., Zhao, X., Sloat, L. M., Azin, M., Wang, J., Collier, M. R., Tummala, K. S., Mandinova, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48441-8 · Cited by 48
Lipid metabolism in homeostasis and disease
Li, Z., Deng, W., Yang, L., Tang, C., Yue, J.-M., Monteiro, O., Baptista‐Hon, D. T., & Li, T. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02357-x · Cited by 58
Gui, Y., Liao, C.-X., Liu, Q., Guo, Y., Yang, T., Chen, J., Wang, Y., Hu, J., & Xu, D. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317691874 · Cited by 48
Recent Advances in Human Genetics and Epigenetics of Adiposity: Pathway to Precision Medicine?
Fall, T., Mendelson, M., & Speliotes, E. K. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.054 · Cited by 50
Knowns and unknowns in the care of pediatric familial hypercholesterolemia
Martin, A. C., Gidding, S. S., Wiegman, A., & Watts, G. F. (2017) · Journal of Lipid Research · doi:10.1194/jlr.s074039 · Cited by 48
Webster, R., Weinman, J. A., & Rubin, G. J. (2018) · Annals of Behavioral Medicine · doi:10.1093/abm/kax064 · Cited by 48
Ponce, O. J., Larrea-Mantilla, L., Hemmingsen, B., Serrano, V., Rodríguez‐Gutiérrez, R., Spencer‐Bonilla, G., Álvarez‐Villalobos, N. A., Benkhadra, K., Haddad, A., Gionfriddo, M. R., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00195 · Cited by 48
Helkkula, P., Kiiskinen, T., Havulinna, A. S., Karjalainen, J., Koskinen, S., Salomaa, V., Daly, M. J., Palotie, A., Surakka, I., Ripatti, S., et al. (2021) · PLOS Genetics · doi:10.1371/journal.pgen.1009501 · Cited by 47
Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition
Kettunen, J., Holmes, M. V., Allara, E., Anufrieva, O., Ohukainen, P., Oliver-Williams, C., Wang, Q., Tillin, T., Hughes, A. D., Kähönen, M., et al. (2019) · PLOS Biology · doi:10.1371/journal.pbio.3000572 · Cited by 47
Self-citationCastelijns, M. C., Helmink, M. A. G., Hageman, S. H. J., Asselbergs, F. W., de Borst, G. J., Bots, M. L., Cramer, M. J., Dorresteijn, J. A. N., Emmelot‐Vonk, M. H., Geerlings, M. I., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-066952 · Cited by 47
Reith, C. A., Blackwell, L. S., Emberson, J., Preiss, D., Spata, E., Davies, K., Halls, H. J., Harper, C., Holland, L., Wilson, K., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(25)01578-8 · Cited by 51
Self-citationMcFarland, A. J., Davey, A. K., & Anoopkumar‐Dukie, S. (2017) · Mediators of Inflammation · doi:10.1155/2017/2582745 · Cited by 48
Nocebo/drucebo effect in statin-intolerant patients: an attempt at recommendations
Penson, P. E., & Banach, M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab358 · Cited by 48
Desai, N. R., Campbell, C., Electricwala, B., Petrou, M., Trueman, D., Woodcock, F., & Cristino, J. R. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00534-9 · Cited by 47
Nishikido, T. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01752-4 · Cited by 45
Statins and diabetes: What are the connections?
Sattar, N. A. (2023) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2023.101749 · Cited by 46
Brunham, L. R., Lonn, E., & Mehta, S. R. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.04.017 · Cited by 54
Lieb, W., Enserro, D. M., Larson, M. G., & Vasan, R. S. (2018) · Open Heart · doi:10.1136/openhrt-2017-000722 · Cited by 46
Metadata
- Authors
- Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., Evans, S., Law, M., MacMahon, S., Martin, S., Neal, B., Poulter, N., Preiss, D., Ridker, P., Roberts, I., Rodgers, A., Sandercock, P., Schulz, K., Sever, P., Simes, J., Smeeth, L., Wald, N., Yusuf, S., & Peto, R.
- Affiliations
- University of Oxford (GB)
- Johns Hopkins University (US)
- University of Cambridge (GB)
- University of Bristol (GB)
- University of Wisconsin–Madison (US)
- University of London (GB)
- The University of Sydney (AU)
- Imperial College London (GB)
- Brigham and Women's Hospital (US)
- University of Edinburgh (GB)
- University of North Carolina at Chapel Hill (US)
- Population Health Research Institute (CA)
- Corresponding author
- Collins, Rory
- ORCID
- Collins, Rory
- Reith, Christina
- Emberson, Jonathan
- Armitage, Jane
- Baigent, Colin
- Blumenthal, Roger
- Danesh, John
- Smith, George Davey
- DeMets, David
- Evans, Stephen
- MacMahon, Stephen
- Martin, Seth
- Neal, Bruce
- Poulter, Neil
- Preiss, David
- Ridker, Paul
- Roberts, Ian
- Rodgers, Anthony
- Sandercock, Peter
- Schulz, Kenneth
- Smeeth, Liam
- Wald, Nicholas
- Yusuf, Salim
- Peto, Richard
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2016-11
- Volume
- 388
- Issue
- 10059
- Pages
- 2532-2561
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2519634482
- Cited by
- 1,857
- References
- 299
- Citations by year
- 2026: 136 · 2025: 136 · 2024: 150 · 2023: 166 · 2022: 187 · 2021: 229 · 2020: 192 · 2019: 218 · 2018: 206 · 2017: 202 · 2016: 31
- FWCI
- 43.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Explore Bristol Research (publishedVersion, other-oa)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by-nc-nd)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
- Funders
- Cancer Research UK (16896)
- National Institute for Health and Care Research (NF-SI-0611-10057, HTA/14/49/159, 14/49/159, NF-SI-0513-10059)
- British Heart Foundation (SP/08/010/25939, SP/14/3/31114, RG/13/13/30194)
- Medical Research Council (MR/K006584/1, MR/L003120/1)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- statin therapy, LDL cholesterol lowering, cardiovascular disease prevention, secondary prevention, primary prevention, absolute risk reduction, statin adverse effects, myopathy, rhabdomyolysis, new-onset diabetes, hemorrhagic stroke, atorvastatin, long-term treatment, evidence evaluation, cardiovascular risk assessment, cost-effectiveness, randomized controlled trials, meta-analysis
- MeSH terms
- Anticholesteremic Agents, Clinical Trials as Topic, Coronary Disease, Humans, Cholesterol, LDL, Myocardial Infarction, Safety, Risk Assessment, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Stroke, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
